MHRA launches new pharmacovigilance reporting platform for COVID-19 treatments
pharmafile | May 5, 2020 | News story | Manufacturing and Production, Research and Development | COVID-19, MHRA, UK, coronavirus, pharma
A new online reporting site has been launched by the Medicines and Healthcare products Regulatory Agency’s (MHRA) to track potential side-effects arising from the use of any therapies used to treat COVID-19, in a bid to build a knowledge base around safe treatment of the pandemic disease.
The Yellow Card COVID-19 reporting site is designed to streamline reporting of adverse events for patients, carers and healthcare professionals and provide an essential pharmacovigilance resource in anticipation of a wave of potential therapies for the virus becoming available in the coming months.
The platform aims to identify potential risks in developed treatments, vaccines, diagnostics or medical devices, including when used off-label, which may emerge as treatments efforts are scaled up worldwide, with the MHRA then using this growing resource to take regulatory action, where appropriate. This includes new information not previously known on medicines to manage long-term pre-existing conditions which may interact with potential COVID-19 therapies.
“While our aim is to ensure that potentially lifesaving COVID-19 treatments and medical equipment reach patients as quickly as possible, patient safety is our highest priority,” explained Dr June Raine, MHRA Chief Executive. “I encourage healthcare professionals and patients to use our new dedicated site to report problems with medical equipment, including ventilators or testing kits, as well as any suspected side effects from medicines used to combat COVID-19.”
Matt Fellows
Related Content
IMed Consultancy releases white paper on Digital Mental Health Technologies
IMed Consultancy, a consultancy and service provider for the medical and health technology sector, has …
COVID-19 vaccine eligibility creates challenges for UK pharmacies
Pharmacists across England have reported widespread confusion among patients attempting to book COVID-19 vaccination appointments …
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
